Context Therapeutics Inc. (NASDAQ:CNTX) Short Interest Update

Context Therapeutics Inc. (NASDAQ:CNTX) saw a significant decrease in short interest in the month of November. As of November 15th, there was short interest totalling 879,600 shares, a decrease of 13.8% from the October 31st total of 1,020,000 shares. Based on an average daily trading volume, of 278,800 shares, the days-to-cover ratio is presently 3.2 days. Approximately 1.5% of the company’s stock are short sold.

Context Therapeutics Price Performance

Shares of NASDAQ:CNTX opened at $1.56 on Tuesday. The stock has a market capitalization of $117.00 million, a PE ratio of -1.71 and a beta of 2.25. The company’s 50-day moving average price is $1.92 and its two-hundred day moving average price is $2.07. Context Therapeutics has a one year low of $0.79 and a one year high of $2.75.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.11). On average, analysts anticipate that Context Therapeutics will post -0.51 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on CNTX. D. Boral Capital initiated coverage on shares of Context Therapeutics in a report on Monday, November 25th. They set a “buy” rating and a $9.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $6.00 price target on shares of Context Therapeutics in a research note on Monday, September 23rd. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $6.80.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Y Intercept Hong Kong Ltd acquired a new position in Context Therapeutics during the third quarter worth approximately $89,000. Renaissance Technologies LLC lifted its position in Context Therapeutics by 63.4% during the second quarter. Renaissance Technologies LLC now owns 65,200 shares of the company’s stock worth $131,000 after acquiring an additional 25,300 shares during the last quarter. State Street Corp lifted its holdings in Context Therapeutics by 21.5% during the 3rd quarter. State Street Corp now owns 111,907 shares of the company’s stock worth $219,000 after purchasing an additional 19,800 shares during the last quarter. Affinity Asset Advisors LLC grew its holdings in Context Therapeutics by 392.4% in the 2nd quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company’s stock valued at $3,246,000 after buying an additional 1,290,323 shares in the last quarter. Finally, Franklin Resources Inc. bought a new stake in shares of Context Therapeutics in the third quarter valued at about $3,689,000. Institutional investors own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.